Diagnostic Pitfalls of HIV‑ Associated Kaposi Sarcoma

Česká verzia

Authors: D. Vaňousová ¹; D. Jilich ²; L. Machala ^3,4; M. Hósová ⁵; L. Pock ⁶; H. Rozsypal ²; Staňková M. Hercogová J. ^{7 1}
Authors place of work: Dermatovenerologická klinika FN Na Bulovce, Praha ¹; Klinika infekčních a tropických nemocí, 1. LF UK v Praze a FN na Bulovce, Praha ²; 1. infekční klinika 2. LF UK a IPVZ, Praha ³; Patologicko‑anatomické oddělení FN Na Bulovce, Praha ⁴; Klinika infekčních nemocí, 3. LF UK, Praha ⁵; Dermatohistopatologická laboratoř s. r. o., Praha ⁶; Infekční klinika FN Na Bulovce, Praha ⁷
Published in the journal: Klin Onkol 2010; 23(5): 285-292
Category: Reviews

Summary

Kaposi sarcoma was one of the very first diseases which indicated the advent of the AIDS pandemic. Despite the marked fall in its occurrence thanks to the introduction of the cART, Kaposi sarcoma remains the most frequent tumour in HIV‑ positive patients and still represents a major diagnostic and therapeutic problem. Particularly in the early stages both the macroscopic and histopatological picture of Kaposi sarcoma may be very atypical, which can cause diagnostic difficulties right at the time when an early therapy may be most successful. In order to improve both the diagnostics and therapy of Kaposi sarcoma, close collaboration between physicians taking care of HIV‑ positive patients – mainly infectologists, dermatologists and pathologists, is necessary.

Key words:
Kaposi sarcoma – HIV – AIDS – histopathology – differential diagnosis

Zdroje

1. Gottlieb GJ, Ragaz A, Vogel JV et al. A preliminary communication on extensively disseminated Kaposi‘s sarcoma in young homosexual men. Am J Dermatopathol 1981; 3(2): 111– 114.

2. Hymes KB, Cheung T, Greene JB et al. Kaposi‘s sarcoma in homosexual men – a report of eight cases. Lancet 1981; 2(8247): 598– 600.

3. Friedman‑ Kien AE, Laubenstein LJ, Rubinstein P et al. Disseminated Kaposi‘s sarcoma in homosexual men. Ann Intern Med 1982; 96(6 Pt 1): 693– 700.

4. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 1872; 4: 265– 273.

5. Vorlíček J, Slavík M. Kaposiho sarkom po sto dvaceti letech. Klin Onkol 1991; 4(3): 75– 83.

6. Ziegler JL, Templeton AC, Vogel CL. Kaposi‘s sarcoma: a comparison of classical, endemic, and epidemic forms. Semin Oncol 1984; 11(1): 47– 52.

7. Goedert JJ, Vitale F, Lauria C et al. Classical Kaposi‘s Sarcoma Working Group. Risk factors for classical Kaposi‘s sarcoma. J Natl Cancer Inst 2002; 94(22): 1712– 1718.

8. Guttman‑ Yassky E, Bar‑ Chana M, Yukelson A et al. Epidemiology of classic Kaposi‘s sarcoma in the Israeli Jewish population between 1960 and 1998. Br J Cancer 2003; 89(9): 1657– 1660.

9. Chang Y, Ziegler J, Wabinga H et al. Kaposi‘s sarcoma‑associated herpesvirus and Kaposi‘s sarcoma in Africa. Uganda Kaposi‘s Sarcoma Study Group. Arch Intern Med 1996; 156(2): 202– 204.

10. Amir H, Kaaya EE, Manji KP et al. Kaposi‘s sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children. Pediatr Infect Dis J 2001; 20(5): 518– 521.

11. Lebbé C, Legendre C, Frances C. Kaposi sarcoma in transplantation. Transplant Rev (Orlando) 2008; 22(4): 252– 261.

12. Schwartz RA, Micali G, Nasca MR et al. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 2008; 59(2): 179– 206; quiz 207– 208.

13. Šlampa P. Maligní nádory při syndromu získaného selhání imunity (AIDS). Klin Onkol 1989; 2(6): 183– 185.

14. Gallafent JH, Buskin SE, De Turk PB et al. Profile of patients with Kaposi‘s sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 23(6): 1253– 1260.

15. Mocroft A, Kirk O, Clumeck N et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994– 2003: the EuroSIDA Study. Cancer 2004; 100(12): 2644– 2654.

16. Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS‑related malignancies – the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2005; 2(8): 406– 415; quiz 423.

17. NRL pro AIDS, SZÚ, Praha. Nové případy HIV infekce a onemocnění AIDS, údaje ke dni 31. 12. 2009. [http:/ / www.aids‑ hiv.cz/ nove09/ JS12– 2009.pdf]. Accessed April 1, 2010.

18. Dvořáková K, Hercogová J, Rozsypal H et al. Kožní projevy u HIV‑pozitivních pacientů (studie z období 1985 – 1998). Čes‑ slov Derm 2001; 76(5): 227– 236.

19. Humphrey RW, Davis DA, Newcomb FM et al. Human herpesvirus 8 (HHV‑ 8) in the pathogenesis of Kaposi‘s sarcoma and other diseases. Leuk Lymphoma 1998; 28(3– 4): 255– 264.

20. Ablashi DV, Chatlynne LG, Whitman JE jr. et al. Spectrum of Kaposi‘s sarcoma‑associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 2002; 15(3): 439– 464.

21. Wen KW, Damania B. Kaposi sarcoma‑associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Lett 2010; 289(2): 140– 150.

22. Cannon MJ, Laney AS, Pellett PE. Human herpesvirus 8: current issues. Clin Infect Dis 2003; 37(1): 82– 87.

23. Martin JN, Ganem DE, Osmond DH et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338(14): 948– 954.

24. Suchankova A, Stankova M, Roubalova K et al. Seroprevalence of HHV 8 antibodies among the general population and HIV positive persons in the Czech Republic. J Clin Virol 2003; 28(1): 70– 76.

25. Pantanowitz L, Moses AV, Dezube BJ. The inflammatory component of Kaposi sarcoma. Exp Mol Pathol 2009; 87(2): 163– 165.

26. Boshoff C, Schulz TF, Kennedy MM et al. Kaposi‘s sarcoma‑associated herpesvirus infects endothelial and spindle cells. Nat Med 1995; 1(12): 1274– 1278.

27. Foster CB, Lehrnbecher T, Samuels S et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96(7): 2562– 2567.

28. Lehrnbecher TL, Foster CB, Zhu S et al. Variant genotypes of FcgammaRIIIA influence the development of Kaposi‘s sarcoma in HIV‑ infected men. Blood 2000; 95(7): 2386– 2390.

29. Bottero V, Sharma‑ Walia N, Kerur N et al. Kaposi sarcoma‑associated herpes virus (KSHV) G protein‑coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression. Virology 2009; 392(1): 34– 51.

30. Hong YK, Foreman K, Shin JW et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma‑associated herpesvirus. Nat Genet 2004; 36(7): 683– 685.

31. Chen X, Cheng L, Jia X et al. Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma‑associated herpesvirus Kaposin A‑ mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. Neoplasia 2009; 11(12): 1272– 1284.

32. Mbulaiteye SM, Biggar RJ, Goedert JJ et al. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32(5): 527– 533.

33. Bartlett J, Gallant J. Medical management of HIV infection. Baltimore: Johns Hopkins Medicine Health Publishing Business Group 2004.

34. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV‑ 1- infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133(6): 447– 454.

35. Bower M, Nelson M, Young AM et al. Immune reconstitution inflammatory syndrome associated with Kaposi‘s sarcoma. J Clin Oncol 2005; 23(22): 5224– 5228.

36. Letang E, Almeida JM, Miró JM et al. Predictors of Immune Reconstitution Inflammatory Syndrome‑ Associated With Kaposi Sarcoma in Mozambique: A Prospective Study. J Acquir Immune Defic Syndr 2010; 53(5): 581– 591.

37. Price P, Mathiot N, Krueger R et al. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001; 22(3): 279– 287.

38. Hirsch HH, Kaufmann G, Sendi P et al. Immune reconstitution in HIV‑ infected patients. Clin Infect Dis 2004; 38(8): 1159– 1166.

39. Schwartz RA. Kaposi‘s sarcoma: advances and perspectives. J Am Acad Dermatol 1996; 34(5 Pt 1): 804– 814.

40. Simonart T, Dobbeleer GD, Peny M et al. Pre‑Kaposi‘s sarcoma: an expansion of the spectrum of Kaposi‘s sarcoma lesions. Eur J Dermatol 1999; 9(6): 480– 482.

41. Micali G, Nasca MR, De Pasquale R et al. Primary classic Kaposi‘s sarcoma of the penis: report of a case and review. J Eur Acad Dermatol Venereol 2003; 17(3): 320– 323.

42. Gasparetto TD, Marchiori E, Lourenco S et al. Pulmonary involvement in Kaposi sarcoma: correlation between imaging and pathology. Orphanet J Rare Dis 2009; 4: 18.

43. Pantanowitz L, Dezube BJ. Kaposi sarcoma in unusual locations. BMC Cancer 2008; 8: 190.

44. Lemlich G, Schwam L, Lebwohl M. Kaposi‘s sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty‑ four cases. J Am Acad Dermatol 1987; 16(2 Pt 1): 319– 325.

45. Gorin FA, Bale JF jr, Halks‑ Miller M et al. Kaposi‘s sarcoma metastatic to the CNS. Arch Neurol 1985; 42(2): 162– 165.

46. Eberly LE, Ohman PA, Neaton JD et al. Kaposi‘s sarcoma and central nervous system disease: a real association or an artifact of the control group? Terry Beirn Community Programs for Clinical Research on AIDS. Aids 2000; 14(8): 995– 1000.

47. Real FX, Krown SE. Spontaneous regression of Kaposi‘s sarcoma in patients with AIDS. N Engl J Med 1985; 313(26): 1659.

48. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008; 3: 31.

49. Niedt GW, Myskowski PL, Urmacher C et al. Histology of early lesions of AIDS‑associated Kaposi‘s sarcoma. Mod Pathol 1990; 3(1): 64– 70.

50. Sangüeza OP, Requena L. Malignant neoplasms. Kaposi‘s sarcoma. In: Sangüeza OP, Requena L (eds). Pathology of vascular skin lesions. Clinicopathological correlations. New Jersey: Humana Press 2003; 217– 235.

51. Satta R, Cossu S, Massarelli G et al. Anaplastic transformation of classic Kaposi‘s sarcoma: clinicopathological study of five cases. Br J Dermatol 2001; 145(5): 847– 849.

52. Cannon MJ, Dollard SC, Black JB et al. Risk factors for Kaposi‘s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17(2): 215– 222.

53. Acharya S, Ross JD. Kaposi‘s sarcoma of the recto sigmoid colon in a patient with HIV infection and a high CD4 count. Int J STD AIDS 2007; 18(7): 499– 500.

54. Mocroft A, Youle M, Phillips AN et al. The incidence of AIDS‑ defining illnesses in 4 883 patients with human immunodeficiency virus infection. Royal Free/ Chelsea and Westminster Hospitals Collaborative Group. Arch Intern Med 1998; 158(5): 491– 497.

55. Clifford GM, Franceschi S. Cancer risk in HIV‑ infected persons: influence of CD4(+) count. Future Oncol 2009; 5(5): 669– 678.

56. Polstra AM, Van Den Burg R, Goudsmit J et al. Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS‑associated Kaposi‘s sarcoma. J Clin Microbiol 2003; 41(12): 5488– 5491.

57. Engels EA, Biggar RJ, Marshall VA et al. Detection and quantification of Kaposi‘s sarcoma‑associated herpesvirus to predict AIDS‑associated Kaposi‘s sarcoma. AIDS 2003; 17(12): 1847– 1851.

58. Nuovo M, Nuovo G. Utility of HHV8 RNA detection for differentiating Kaposi‘s sarcoma from its mimics. J Cutan Pathol 2001; 28(5): 248– 255.

59. Alkan S, Eltoum IA, Tabbara S et al. Usefulness of molecular detection of human herpesvirus‑ 8 in the diagnosis of Kaposi sarcoma by fine‑ needle aspiration. Am J Clin Pathol 1999; 111(1): 91– 96.

60. Martellotta F, Berretta M, Vaccher E et al. AIDS‑related Kaposi‘s sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009; 7(6): 634– 638.

61. Hauerstock D, Gerstein W, Vuong T. Results of radiation therapy for treatment of classic Kaposi sarcoma. J Cutan Med Surg 2009; 13(1): 18– 21.

62. Brambilla L, Bellinvia M, Tourlaki A et al. Intralesional vincristine as first‑line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 2010; 162 (4): 854– 859.

63. Presant CA, Scolaro M, Kennedy P et al. Liposomal daunorubicin treatment of HIV‑associated Kaposi‘s sarcoma. Lancet 1993; 341(8855): 1242– 1243.

64. Tulpule A, Groopman J, Saville MW et al. Multicenter trial of low‑dose paclitaxel in patients with advanced AIDS‑related Kaposi sarcoma. Cancer 2002; 95(1): 147– 154.

65. Uneda S, Murata S, Sonoki T et al. Successful treatment with liposomal doxorubicin for widespread Kaposi‘s sarcoma and human herpesvirus‑ 8 related severe hemophagocytic syndrome in a patient with acquired immunodeficiency syndrome. Int J Hematol 2009; 89(2): 195– 200.

66. Adam Z, Vorlíček J. Biologie, farmakologie a přehled léčebného užití interferonů. Klin Onkol 1996; 9(4): 115– 120.

67. Biggar RJ, Engels EA, Ly S et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39(3): 293– 299.

68. Stebbing J, Sanitt A, Nelson M et al. A prognostic index for AIDS‑associated Kaposi‘s sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367(9521): 1495– 1502.

69. Martin‑Carbonero L, Palacios R, Valencia E et al. Long‑term prognosis of HIV‑ infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47(3): 410– 417.

70. Schwartz RA, Spicer MS, Thomas I et al. Ecchymotic Kaposi‘s sarcoma. Cutis 1995; 56(2): 104– 106.

71. Schmid H, Zietz C. Human herpesvirus 8 and angiosarcoma: analysis of 40 cases and review of the literature. Pathology 2005; 37(4): 284– 287.

72. Kang GH, Kwon GY, Kim CW. Human herpesvirus 8 in Kaposi‘s sarcoma and Kaposi‘s sarcoma‑ mimicking vascular tumors. J Korean Med Sci 1998; 13(1): 54– 59.

73. Santa Cruz DJ, Kyriakos M. Aneurysmal („angiomatoid“) fibrous histiocytoma of the skin. Cancer 1981; 47(8): 2053– 2061.

74. Ramirez Ramirez CR, Saavedra S, Ramirez Ronda CH. Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Bol Asoc Med P R 1996; 88(4– 6): 46– 51.

75. Kanitakis J, Narvaez D, Claudy A. Expression of the CD34 antigen distinguishes Kaposi‘s sarcoma from pseudo‑ Kaposi‘s sarcoma (acroangiodermatitis). Br J Dermatol 1996; 134(1): 44– 46.

76. Posada Garcia C, Garcia‑ Cruz A, Garcia‑ Doval I et al. Lymphangioma‑like Kaposi sarcoma: case report. Dermatol Online J 2009; 15(9): 13.

77. Guillou L, Fletcher CD. Benign lymphangioendothelioma (acquired progressive lymphangioma): a lesion not to be confused with well‑differentiated angiosarcoma and patch stage Kaposi‘s sarcoma: clinicopathologic analysis of a series. Am J Surg Pathol 2000; 24(8): 1047– 1057.

78. Lyons LL, North PE, Mac‑ Moune Lai F et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28(5): 559– 568.

79. Armah HB, Parwani AV. Epithelioid sarcoma. Arch Pathol Lab Med 2009; 133(5): 814– 819.

80. Bolander A, Agnarsdóttir M, Wagenius G et al. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res 2008; 18(6): 412– 419.